B2M and urinary bladder cancer: Strategies based on this rationale are the beta-2-microglobulin (B2M) Antibody-Drug Conjugate (ADC), whose efficacy has been tested in vitro in colon and bladder cancer cell lines, and the apolipoprotein D ADC tested in senescent skin fibroblasts both in vitro and in vivo231.